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Abstract 
In the treatment of lung cancer, there is an urgent need of innovative medicines to 
optimize pharmacological responses of conventional chemotherapeutics while attenuating 
side effects. Here, we have exploited some relatively unexplored subtle differences in 
reduction potential, associated with cancer cell microenvironments in addition to the well-
known changes in intracellular redox environment. We report the synthesis and application 
of novel redox-responsive PLGA (poly(lactic-co-glycolic acid)) -PEG (polyethylene glycol) 
nanoparticles (RR-NPs) programmed to change surface properties when entering tumor 
microenvironments, thus enhance cell internalization of the particles and their drug cargo. 
The new co-polymers, in which PEG and  PLGA were linked by ‘anchiomeric effector’ 
dithiylethanoate esters were synthesized by a combination of ring-opening polymerization 
and Michael addition reactions and employed to prepare NPs. Non redox-responsive 
nanoparticles (nRR-NPs) based on related PLGA-PEG copolymers were also prepared as 
comparators. Spherical NPs of around 120 nm diameter with a low polydispersity index and 
negative zeta potentials as well as good drug loading of docetaxel were obtained. The NPs 
showed prolonged stability in relevant simulated biological fluids and a high ability to 
penetrate an artificial mucus layer due to the presence of the external PEG coating. Stability, 
FRET and drug release studies in conditions simulating intracellular reductive environments 
demonstrated a fast disassembly of the external shell of the NPs, thus triggering on-demand 
drug release. 
FACS measurements and confocal microscopy showed increased and faster uptake of RR-
NPs in both 2D- and 3D- cell culture models of lung cancer compared to nRR-NPs. In 
particular, the ‘designed-in’ reductive instability of RR-NPs in conditioned cell media, the fast 
PEG release in the extracellular compartment, as well as a diminution of uptake rate in 
control experiments where extracellular thiols were neutralized, suggested a partial 
extracellular release of the PEG fringe that promoted rapid internalization of the residual 
NPs into cells.  
Taken together, these results provide further evidence of the effectiveness of PEGylated 
reducible nanocarriers to permeate mucus layer barriers, and establish a new means to 
enhance cancer cell uptake of drug carriers by extra-and intra-cellular cleavage of protein- 
and cell-shielding hydrophilic blocks.  
Introduction 
The need for selective therapies and personalized nanomedicines for cancer has 
prompted research into novel formulations which can utilise minimally invasive 
administration routes, and also exploit specific characteristics of the tumor type and its 
localization in the body. Local delivery of anti-cancer drugs to the lungs via inhalable 
formulations could represent a promising strategy to enhance pharmacological targeting and 
efficacy, while maintaining low drug levels at non-target sites and reducing side effects 
related to systemic administration.[1, 2] Better formulations for lung cancer are particularly 
needed because this disease remains one of the leading causes of cancer mortality 
worldwide.  
Despite poly-chemotherapy, close to 70% of patients with lung cancer present locally 
advanced or metastatic disease at the time of diagnosis. In such cases, the prognosis is 
poor and patients with advanced disease commonly die within one year. For this reason, 
many different lung delivery technologies have been explored in order to optimize 
pharmacological response while attenuating side effects of conventional therapies. 
Nevertheless, the biggest obstacles in lung cancer diseases are related to the physiological 
and pathological barriers of the lung, as well as the tumor microenvironment which is highly 
variable among individuals and cancer types/stages. In particular, the success of inhalation 
therapies for severe and chronic lung diseases, including cancer, strongly depends upon: i) 
site and extent of drug deposition in the respiratory tract; ii) drug permeation through airway 
mucus; iii) macrophage clearance escape and iv) interaction with target cells.[3] As a 
consequence, drug delivery carriers which can reach the deep lung and selectively target 
cancer cells are needed.[4, 5]  
Delivery systems based on PEGylated nanoparticles (NPs) have been shown to penetrate 
rapidly across mucus layers, avoiding clearance mechanisms and thereby providing 
targeting to underlining epithelial tissues.[6] However, the properties of the PEG chains, 
including chain length as well as the molecular weight, can affect the conformation and the 
density of the hydrophilic corona on NP surfaces, thus modifying the penetration across 
mucus barriers.[7] In addition, even when accumulated within the deep lung, it is still 
necessary to discriminate between normal cells and the tumor sites, and thus not only is 
mucus-penetration required but also a selective delivery mechanism in situ is needed. 
Accordingly, the development of inhalable NPs which can respond in the tumor 
microenvironment to target specific cells, or to release a therapeutic at a particular site, is of 
significant interest.  
A number of "smart" polymeric NPs have been developed that release drugs in response 
to internal or external stimuli, such as pH, redox potential, up-regulated proteins, 
temperature, magnetic and light, and some have demonstrated improved tumor targeting 
abilities and antitumor effects.[8-10] A particular focus has been to exploit the differences in 
reduction potential between normal tissues and certain cancer cells, since it has been 
established that some tumor intracellular compartments are characterized by reductive 
glutathione (GSH) tripeptides at concentrations (about 2-10 mM), which are 100 - 1000 times 
higher than those in extracellular fluids and normal tissues (about 2-20 μM)[11]. For this 
reason, GSH-responsive NPs have been recognized as promising intracellular drug delivery 
systems for cancer therapy.[12-15]  
Several recent reviews have discussed redox responsive gene delivery polyplexes, 
liposomes, micelles, nanoparticles, gels and antibody–drug conjugates[12, 16, 17].  One 
example is Mylotarg®, which was the first FDA approved drug delivery system containing a 
linker system with a disulfide bond[18], although this product was subsequently withdrawn 
from the market. Although the introduction of disulfide linkages has been shown to enhance 
drug release via well-established intracellular mechanisms, in recent years, some further 
evidence has been obtained that certain reactive and reductive processes can also take 
place in extracellular regions and at cancer cell surfaces due to the presence of extracellular 
thiols and cell surface-associated redox enzymes.[19-21]. For example, Kwok and co-
workers synthesized nonreducible and reducible poly(ethylene glycol) (PEG)‐peptides, and 
reported a higher cellular uptake for the reducible PEG–peptide DNA condensate, indicating 
that extracellular mechanisms might be involved.[22] In support of their findings, Feener et 
al. [19] synthesized a radioiodinated tyramine linked through a disulfide bond to an non-
degradable carrier, poly(D-lysine), known to be efficiently endocytosed. This compound was 
tested in cultured Chinese hamster ovary cells and the disulfide cleavage was measured via 
the release of acid-soluble radioactive products over time. When sulfhydryl groups present 
at the cell surface were blocked with a cell-impermeant sulfhydryl reagent, the initial phase 
of disulfide cleavage was inhibited, indicating that disulfide bond reduction of the reducible 
peptides was initiated at the cell surface. [20] A later study found that reducible polylysine 
based DNA nanoparticles enhanced cellular uptake and in vitro gene transfer via an 
extracellular mechanism, demonstrated by blocking extracellular free thiols. As controls, a 
series of DNA NPs prepared with stabilized disulfide bonds survived the extracellular 
environment without aggregation but lost the superior gene transfer ability[19]. Despite these 
findings, so far no clinically relevant data on in vivo cancer models are available, so a deeper 
investigation of extracellular redox responsiveness is needed. However, it can be envisaged 
that drug delivery systems might be designed which could respond to changes in the surface 
biochemistry and redox potential at cancer cell surfaces, in addition to an intracellular 
response.  
With this in mind, we describe here a novel double extra- and intracellular redox-
responsive polymer intended for inhaled therapy of lung cancer. The key design criteria 
were; 1) a short hydrophilic polymer block to form a mucus-penetrating external layer; 2) a 
disulfide bond specifically placed such that it not only links the external hydrophilic shell to 
a hydrophobic drug-carrying core, but is accessible to extracellular thiols and reducing 
agents at cancer cell surfaces; 3) linker chemistry which generates new nucleophilic species 
on disulfide cleavage and 4) backbone chemistry of the hydrophobic core which allows for 
accelerated degradability upon nucleophile generation. We based our materials design on 
amphiphilic bioreducible polyethylene glycol (PEG)-poly(lactic-co-glycolic acid) (PLGA) 
block copolymers, as these systems are well-known for biodegradability, drug loading 
properties as well as suitability in pulmonary delivery of different drugs[23] and application 
in the clinic.[24] We therefore designed a linear diblock copolymer in which dithiylethanoate 
esters were used to link the PLGA and the PEG blocks such that reductive cleavage of the 
disulfide was predisposed to generate nucleophilic end groups which simultaneously 
liberated the PEG shell from the NPs and started the degradation of the PLGA core. The 
colloidal properties of the NPs, their drug loading abilities and their redox responsiveness in 
a simulated intracellular reductive environment were investigated. As the particles were 
intended for pulmonary administration, the impact of the release of the PEG shell on NP 
transport through a simulated mucus layer was assessed in vitro. Finally, by using Förster 
Resonance Energy Transfer (FRET) methods, we characterized the cell internalization 





















Materials. All solvents and reagents were of analytical or HPLC grade and purchased from 
Sigma or Fisher Scientific unless otherwise stated. Deuterated solvents, and monomers 
glycolide and DL-lactide were from Sigma. The monomers were recrystallized from ethyl 
acetate prior to use. Poly(ethylene glycol) methyl ether (mPEG) and -methoxy--amino 
poly(ethylene glycol) (mPEG-NH2) with Mn = 2.0 kDa were purchased from Iris Biotech 
GmbH (Germany) and dried by azeotropic distillation from toluene prior to use. Docetaxel 
(DTX, MW= 807.88) was purchased from LC laboratories (USA).  1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate (DiL) and 3,3′-dioctadecyloxacarbocyanine 
perchlorate (DiO) were purchased from Life Technologies (UK). Dialysis membrane (MWCO 
3500, regenerated cellulose) was used as received from Spectrapor. Tin (II)-2-
ethylhexanoate (Sn(Oct)2), acryloyl chloride, triethylamine (TEA), dithioethanol, poly(vinyl 
alcohol) (PVA, Mowiol®40–88, Mw~31000), 5,5′-Dithiobis(2-nitrobenzoic acid) (DTNB), 
sodium chloride, potassium phosphate dibasic and potassium phosphate monobasic, 
sodium azide, L-glutathione reduced (GSH), dithiothreitol (DTT), magnesium chloride, 
sterile egg yolk emulsion, mucin, DTPA, potassium chloride, sodium phosphate dibasic, 
sodium sulfate, calcium chloride dehydrated, sodium acetate,  sodium bicarbonate, sodium 
citrate dehydrate, Rhodamine 6G (Rhod6G), Fluorescein Sodium salt Fluo, iodine and 
barium chloride were used as received from Sigma Aldrich.  
 
Synthesis of block copolymers. 
Synthesis of PLGA-PEG block copolymer.  
PLGA-PEG block copolymers were synthesized by ring-opening polymerization (ROP) 
as previously reported using mPEG and Sn(Oct)2 as initiator and catalyst, respectively[25]. 
DL-lactide (2.5 g, 17.5 mmol), glycolide (2.0 g, 17.5 mmol) and mPEG2k (1.4 g, 0.695 mmol) 
were added in a bottleneck flask and heated to 130 °C to allow complete melting under a 
nitrogen atmosphere for 1h. Sn(Oct)2 (0.5% w/w, 29.5 mg, 0.007 mmol) was then added, 
and the mixture was stirred at 140 °C for 24h. The reaction mixture was cooled down to 
room temperature and the synthesized polymer was recovered by dissolution in DCM and 
precipitated in ice-cold diethyl ether three times to remove the excess of unreacted 
monomers and the catalyst. Finally, the precipitate was filtered and dried under reduced 
pressure to give a white solid product in 86% yield.  
 ATR-IR:  (cm-1) 3510, 2989, 2952, 2883, 1746, 1407, 1162, 1090.  
1H NMR (400 MHz, CDCl3, ppm):  1.52-1.58 (m, 150, -CHCH3), 3.36 (s, 3, -OCH3), 
3.62-3.64  (m, 176, -OCH2CH2O-), 4.78-4.88 (m, 104, -COCH2-), 5.13-5.23 (m, 50 -
COCHCH3).  
13C NMR (400 MHz, CDCl3, ppm): C  16.5 (s, 1, -CHCH3), 60.8 (s, 1, -OCH2OH), 69.0 (s, 
2, -OCH2CH2O-), 70.5 (s, 1, -CHCH3), 166.3 (s,1, -OCOCH-) 169.3 (s, 1, -OCOCH2OH). 
 
Synthesis of PLGA-ss-PEG block copolymer.  
(1) Synthesis of 2-((hydroxymethyl) disulfanyl) ethyl acrylate. The ROP initiator was 
prepared via a reported method with minor modifications[26]. Briefly, dithiodiethanol (10 g, 
0.065 mol) was added to a round-bottom flask equipped with three-way stopcocks 
connected to either a nitrogen line or a vacuum pump, and dried via azeotropic distillation 
with anhydrous toluene (3 x 20 mL) under reduced pressure. After complete evaporation of 
toluene, anhydrous THF (20 mL) was added via a syringe under inert atmosphere. TEA (6.5 
g, 0.065 mol) was added to the solution which was maintained at 4 °C during drop wise 
addition of acryloyl chloride (3.5 g, 0.039 mol). The solution was allowed to warm to room 
temperature under magnetic stirring and left to react overnight. The solution was finally 
filtered to remove the chloride salt of TEA and the crude product was recovered by 
evaporation of THF. The product was purified by passing through silica column 
chromatography using petroleum ether/ ethyl acetate 70:30 as eluents (yield 65%).  
ATR-IR:  (cm-1) 3417, 2934, 2875, 1717, 1638, 1615, 1450, 1407, 1302, 1262, 1180, 
1049, 980.   
1H NMR (400 MHz, d6-DMSO, ppm): 2.85-2.88 (t, 2, J= 12 Hz, -SCH2CH2OH), 2.93-
2.96 (t, 2, J= 12 Hz,  -COOCH2CH2S-), 3.84-3.87 (t, 2, J= 12 Hz,  -CH2OH), 4.39-4.42 (t, 2, 
J= 12 Hz, -COOCH2CH2S-), 5.84-5.87 (dd, 1, J= 8 Hz, J= 0.08 Hz,  -CHCHH), 6.08-6.14 (m, 
1, -CHCHH), 6.39-6.44 (dd, 1, J= 8 Hz, J= 0.08 Hz,  -CHCHH). 
13C NMR (400 MHz, d6-DMSO, ppm): C  36.7 (s, 1, -SCH2CH2O-), 41.2 (s, 1, -
SCH2CH2OH), 60.2 (s, 1, -CH2OH), 62.3 (s, 1, -SCH2CH2O-), 127.8 (s, 1, -CHCH2), 131.4 
(s, 1, -CHCH2), 166.1 (s, 1, -OCOCH-).  
 
 (2) Synthesis of PLGA-S-S-ethyl acrylate.  PLGA-S-S-ethyl acrylate (PLGA-SS) was 
synthesized by ROP using 2-((hydroxymethyl) disulfanyl) ethyl acrylate as initiator. DL-
lactide (2.5 g, 0.0175 mol), glycolide (2.0 g, 0.0175 mol) and 2-((hydroxymethyl) disulfanyl) 
ethyl acrylate (0.144 g, 0.695 mmol) were added in a bottleneck flask and heated to 130 °C 
for complete melting under nitrogen atmosphere for 1h. 0.5% w/w Sn(Oct)2 (29.5 mg, 0.007 
mmol) was then added, and the mixture was stirred at 140 °C for 24h. The synthesized 
polymer was recovered by dissolution in DCM and precipitated in ice-cold diethyl ether three 
times to remove the unreacted monomers. Finally, the precipitate was filtered and dried 
under reduced pressure to give a white solid product in 95% yield.  
ATR-IR:  (cm-1) 3513, 2996, 2960, 2882, 1740, 1424, 1384, 1158, 1118, 1082, 668.  
1H NMR (400 MHz, CDCl3, ppm):  1.57-1.61 (m, 150, -CHCH3), 2.94-3.00 (m, 4, -
CH2SCH2-), 4.27-4.32 (m, 2, -COOCH2CH2S-), 4.43-4.48 (m, 2, -SCH2CH2OCOCH-), 4.70-
4.93 (m, 104, -CH2OH), 5.20-5.26 (m, 50 -COCHCH3), 5.88-5.91 (d, 1, J= 8 Hz, J= 0.08 Hz,  
-CHCHH), 6.12-6.19 (m, 1, -CHCHH), 6.44-6.48 (dd, 1, J= 8 Hz, J= 0.08 Hz,  -CHCHH). 
13C NMR (400 MHz, CDCl3, ppm): C  16.5 (s,1, -CHCH3), 60.8 (s,1, -CH2OH), 65.7 (s, 2, 
CH2CH2SSCH2CH2), 69.1 (s,1, -CHCH3), 166.2 (s,1, -OCOCH-), 169.3 (s,1, -OCOCH2). 
 
(3) Synthesis of PLGA-S-S-PEG. The block copolymer PLGA-S-S-PEG was synthesized 
by Aza-Michael Addition between the amino group of mPEG-NH2 and the acrylic end group 
of PLGA-SS. mPEG-NH2 (2 g, 0.001 mol), PLGA-SS (2.5 g, 0.5 mmol) and TEA (0.1 g, 
0.001 mol) were added to a round-bottom flask equipped with three-way stopcocks 
connected to either a nitrogen line or a vacuum pump, and dried via azeotropic distillation 
with anhydrous toluene (3 x 20 mL) under reduced pressure. After complete evaporation of 
toluene, anhydrous THF (10 mL) was added via a syringe under inert atmosphere. TEA (0.1 
g, 0.001 mol) was added to the solution which was maintained under magnetic stirring at 65 
°C for 6 days. The synthesized polymer was filtered, precipitated in ice-cold diethyl ether 
(twice) and ice-cold methanol (twice) to remove the unreacted reagents, and finally dried 
under reduced pressure to yield a white solid product (yield 70%).  
 ATR-IR:  (cm-1) 3509, 2997, 2957, 2881, 1740, 1417, 1161, 1125, 1075, 668. 
1H NMR (400 MHz, CDCl3, ppm):  1.57-1.61 (m, 150, -CHCH3), 3.13-3.19 (m, 4, - 
CH2SSCH2-) 3.40 (s, 3, -OCH3), 3.66-3.68 (m, 176, -OCH2CH2O-), 4.28-4.33 (m, 2, -
SCH2CH2OCOCH-), 4.79-4.93 (m, 104, -COCH2-), 5.17-5.27 (m, 50 -COCHCH3).  
  13C NMR (400 MHz, CDCl3, ppm): C  16.5 (s, 1, -CHCH3), 40.3 (s, 2, -CH2SSCH2-), 60.8 
(s, 1, -OCH3),  69.0 (s, 2, -OCH2CH2-), 70.5 (s, 1, -CHCH3), 166.3 (s,1, -OCOCH-), 169.3 
(s,1, -OCOCH2). 
 
Characterization of polymers 
Spectroscopy: 1H- and 13C NMR spectra were recorded at 25 °C on a Bruker Avance III 
400 MHz spectrometer. All chemical shifts are reported in ppm (δ) relative to 
tetramethylsilane or referenced to the chemical shifts of residual solvent resonances. 
Multiplicities are described with the following abbreviations: s = singlet, br = broad, d = 
doublet, t = triplet, m = multiplet, dd= doublet of doublets. Chemical shifts were assigned in 
parts per million (ppm). MestReNova 6.0.2 copyright 2009 (Mestrelab Research S. L.) was 
used for analysing the spectra. 
FT-IR spectra were recorded with an Attenuated Total Reﬂection spectrophotometer 
(Agilent Technologies Cary 630 FTIR) equipped with a diamond single reﬂection ATR unit. 
Mass spectrometry was carried out using a Micromass LCT ToF with electrospray ionization 
and OpenLynx software. IR analysis were performed by using SpectraGryph version1.0. 
Chromatography: Size exclusion chromatography (SEC) measurements of PLGA-based 
copolymers were performed at 25 °C by using a PL50 Polymer Laboratories system 
equipped with a refractive index detector, employing 2 mixed bed PLgel Mixed-D columns 
(5 μm bead, 7.8 × 300 mm) columns with a matching guard (7.8 × 50 mm), using CHCl3 as 
the mobile phase at a ﬂow rate of 1 mL/min, and polystyrene standards as reference 
(526000-820 g/mol) in CHCl3. Sample concentration of 5 mg/mL were employed. Molecular 
weights and dispersity values were calculated using Cirrus GPC 3.0 software. 
Thermal analysis: Thermal properties of the materials were studied by differential 
scanning calorimetry (DSC) (Q2000, TA Instruments, Leatherhead, UK) at a heating rate of 
10 °C/min.  The data were analysed using Thermal Analysis Software (Version 4.5.05A). 
Hermetic crimped pans were utilized for the analysis of the samples, using empty pans as 
the reference and the DSC cell was purged with N2(g) at a flow rate of 50 ml/min. Thermal 
transitions were analysed in the temperature range between – 40 to 120 °C.  
 
Nanoparticles preparation and characterization 
Preparation of Nanoparticles. NPs were prepared by the double emulsion–solvent 
evaporation method. In a typical procedure, 0.1 mL of an internal water phase was added 
to a DCM solution (1 mL) of the copolymer (10 mg), and sonicated for 1 min at 3W (Sonicator 
3000, Misonix, USA) by a microtip probe. This first emulsion was poured in water (10 mL) in 
the presence of PVA 0.5% w/v, and sonicated again for 5 min at 3W. Thereafter, the organic 
solvent was evaporated by mechanical stirring for 4 h at r.t. and then filtered (0.45 m). NPs 
were collected by centrifugation (17000 xg, 30 min, 4 °C) after washing twice with distillated 
water to remove PVA. NPs were then redispersed in water (1 mL), freeze-dried for 24 h and 
kept at 4°C. Recovery yield of production process was evaluated by weighing the solid 
residue after freeze-drying. Results are expressed as the ratio of the actual NPs weight to 
the theoretical polymer weight x 100. 
Size, zeta potential and morphological studies. The hydrodynamic diameter (DH), 
polydispersity index (PI) and zeta potential of NPs were determined on a Zetasizer Nano ZS 
(Malvern Instruments Ltd.). A NP dispersion was diluted in Milli-Q water at intensity in the 
range 104-106 counts/s and measurements were performed at 25°C on 90° angle. Results 
are reported as the mean of three separate measurements of three different batches (n=9) 
± standard deviation (SD). The morphology of the NPs was examined by transmission 
electron microscopy (TEM). Samples were imaged using a JEOL (JEM-10-10) electron 
microscope. A few drops were added onto a copper grid and allowed to dry in air. NPs were 
negatively stained with 2% phosphotungstic acid solution. 
Colloidal stability of NPs. Fixed aqueous layer thickness (FALT) was measured by 
monitoring the influence of ionic strength on particle zeta potential. Different amounts of 
NaCl stock solutions at different concentrations were added to a NP dispersion in water (0.5 
mg/mL) and  potentials of the samples were measured. A plot of ln () against (= 3.33 
c0.5NaCl) gives a straight line where the slope represents the thickness of the PEG shell in 
nm (dshell) [27, 28]. To determine the stability of NPs under physiologically relevant 
conditions, a known amount of NPs was dispersed in 10 mM phosphate buffer saline at pH 
7.4 containing sodium chloride (137 mM) and potassium chloride (2.7 mM) (PBS), NaCl 
0.9% w/v or Simulated Interstitial Lung Fluid (SILF) and incubated at 37 °C for different 
times. SILF was prepared following the preparation instructions dictated by Marques et al. 
[29]. Briefly, 1 L of SILF contains 0.095 g of MgCl2, 6.019 g of NaCl, 0.298 g of KCl, 0.126 
g of sodium phosphate dibasic, 0.063 g of sodium sulfate, 0.368 g of calcium chloride 
dehydrated, 0.574 g of sodium acetate, 2.604 g of sodium bicarbonate and 0.097 g of 
sodium citrate dehydrate.  Size measurements of the samples were taken after 1 h, 24 h, 
48 h and 72 h of incubation. The stability of NPs was demonstrated by the absence of 
macroscopic aggregates and unchanged initial particle size. 
Encapsulation studies. NPs were loaded with both hydrophilic and hydrophobic drug 
models, alone and in combination. In particular, Rhod6G and FITC were selected as 
hydrophilic compounds whereas DiL and DiO were chosen as lipophilic tracers. Loaded NPs 
were prepared by the double emulsion-solvent evaporation method as described above. 
Before the emulsion processes, Rhod6G (0.1 mg) md Fluo (0.02 mg) were dissolved in the 
internal water phase, alone or in association, thus forming Rhod6G-NPs, Fluo-NPs and 
Rhod6G/Fluo-NPs. DiL (0.1 mg) and DiO (0.1 mg) were dissolved in the DCM solution 
containing the polymer, alone or in association, thus giving DiL-NPs, DiO-NPs and DiL/DiO-
NPs. 
Rhod6G and Fluo loading inside NPs was assessed by dissolving 1 mg of freeze dried 
NPs in 500 L of DCM under stirring for 1 h. Thereafter, 500 L of water were added and 
the sample stirred for 1 h further. After centrifugation at 5000 rpm for 10 min, the supernatant 
was collected and analysed for Rhod6G and Fluo quantification by UV spectrophotometry 
(Varian Cary Eclipse, UK) at 528 and 490 nm, respectively. The concentration of Rhod6G 
and/or  Fluo was calculated by means of a standard calibration curve derived for water 
solutions of the specific drug at known concentrations (0.4–20 g/mL). Potential interference 
of Rhod6G on Fluo absorbance was preliminary assessed spiking a Fluo solution in water 
with different amount of Rhod6G. Potential interference of Fluo on Rhod6G absorbance was 
preliminary assessed spiking a Rhod6G solution in water with different amount of Fluo. DiL 
and DiO loading inside NPs was assessed by dissolving 1 mg of freeze dried NPs in 1 mL 
of DCM under stirring for 1 h. Samples were analysed for DiL and DiO quantification by UV 
spectrophotometry at 543 and 488 nm, respectively. The concentration of DiL and/or DiO 
was calculated by means of a standard calibration curve derived for DCM solutions of the 
specific drug at known concentrations (0.5–60 g/mL). Potential interferences of DiL on DiO 
absorbance and vice versa were assessed by spiking a DiO solution in DCM with different 
amounts of DiL, or a DiL solution in DCM with different amount of DiO. To verify a possible 
interference of copolymers on DiL/DiO quantitative analysis, an amount of unloaded NPs 
was dissolved in DCM and analysed under the same conditions reported for the drugs.  
 
Redox responsiveness of nanoparticles 
NP stability. To determine the stability of NPs under reductive conditions, a known 
amount of NPs was dispersed in PBS 10 mM pH 7.4 enriched with GSH (5, 10 and 20 mM) 
or DTT (10 mM) (NP concentration was 1.5 mg/mL) and incubated at 37 °C for different 
times. Size measurements of the samples were taken by dynamic light scattering on a 
Zetasizer and a Viscotek 802 instrument after 30 min and 24 h of incubation.  
 Release studies. In vitro release of Rhod6G from NPs in PBS with or without GSH 10 
mM was investigated by a dialysis method. A known amount of NPs (2 mg) was dispersed 
in 0.5 mL of PBS solution and placed in a dialysis bag (MWCO=3500 Da, Spectra/Por®). 
The sample was placed in 8 mL of PBS (sink condition) and kept at 37°C. At selected time 
intervals, 1 mL of release medium was withdrawn and replaced with an equal volume of 
fresh medium. Drug quantitative analysis was performed as described above. Release 
profiles of free drugs are reported for comparison. Results are expressed as release % over 
time ± SD of three experiments. 
Morphological studies. The morphology of the NPs dispersed in PBS pH 7.4 enriched 
with GSH 10 mM was examined by TEM as described above.  
FRET studies. Redox responsiveness of NPs was also evaluated by Förster resonance 
energy transfer (FRET) by co-encapsulating two different fluorescence probes (FRET pairs) 
into NP cores as described above. The hydrophobic dye DiO was chosen as the fluorescent 
donor and DiL as the acceptor molecule. FRET NPs were incubated in PBS with or without 
GSH 10 mM ([NPs]= 1 mg/mL) at 37 °C. The ratio between the maximum intensity of 
emission bands for DiL and DiO was monitored as function of time. Decrease of this ratio 
was considered indicative of NP aggregation or disassembly in the medium. Finally, 
fluorescence emission spectra of FRET NPs were collected at ex 488 nm.  
 
Preparation of anticancer NPs 
DTX loaded NPs were prepared by the double emulsion–solvent evaporation method 
as previously described. In particular, before the emulsion processes, DTX (0.1 mg) was 
dissolved in the DCM solution containing the polymer. Emulsion and purification of NPs were 
carried out as described before. Recovery yield of production process was evaluated by 
weighing the solid residue after freeze-drying. Results are expressed as the ratio of the 
actual NPs weight to the theoretical polymer weight x 100. 
The hydrodynamic diameters (DH), polydispersity indices (PDI) and zeta potentials of NPs 
were determined on a Zetasizer Nano ZS (Malvern Instruments Ltd.) as previously 
described. DTX loading inside NPs was assessed by dissolving 1 mg of freeze-dried NPs in 
1 mL of THF under stirring for 1h. Thereafter the sample was filtered through a 0.22 μm filter 
and analyzed for DTX content by HPLC on a Shimadzu apparatus equipped with a LC-
10ADvp pump, a SIL-10ADvp autoinjector, a SPD-10Avp UV-Vis detector and a C-R6 
integrator. The analysis was performed on a ACE 5m, C18 column (250 x 4.6 mm, Å) 
(Phenomenex, USA). The mobile phase was a 40:60 (v/v) mixture of 20 mM phosphate 
buffer at pH 4.5 and acetonitrile pumped at a flow rate of 1 mL/min. The UV detector was 
set at 227 nm. A calibration curve for DTX in THF was constructed in the concentration 
range 1 – 200 µg/mL. The limits of quantitation (LOQ) and detection (LOD) in 
acetonitrile:water 50:50 (v/v) were 1.29 and 0.39 g/mL. 
In vitro release of DTX from NPs in PBS with or without GSH 10 mM was investigated by a 
dialysis method. A known amount of NPs (2 mg) was dispersed in 0.5 mL of PBS solution 
and placed in a dialysis bag (MWCO=3500 Da, Spectra/Por®). The sample was plunged in 
8 mL of PBS (sink condition) and kept at 37°C. At selected time intervals, 1 mL of release 
medium was withdrawn and replaced with an equal volume of fresh medium. DTX 
quantitative analysis was performed as described above. Release profile of the free drugs 
is reported for comparison. Results are expressed as release % over time ± SD of three 
experiments. 
 
Interactions with mucin 
The mucoadhesive tendency of NPs was investigated through turbidimetry, size and 
zeta potential measurements of NPs exposed to mucin. Mucin powder was dispersed in 
water (0.08% w/v) and stirred overnight. The dispersion was then centrifuged at 5000 rpm 
for 20 min to collect the mucin-containing supernatant. Unloaded NPs (1 mg) were dispersed 
in 1 mL of mucin dispersion and the samples incubated at 37 °C for 24h. At different time 
points (0, 1 h, 4 h and 24 h), the turbidimetry of the mixtures was measured at 650 nm by 
spectrophotometry. Reference absorbance values of mucin and NP dispersions were also 
evaluated. The hydrodynamic diameter (DH), polydispersity index (PI) and zeta potential of 
NPs were also assessed. The mucus-penetrating properties of fluorescent NPs through 
artificial mucus was investigated too. Briefly, 50 mL of artificial mucus was prepared adding 
500 mg DNA, 250 L of sterile egg yolk emulsion, 250 mg of mucin, 0.295 mg DTPA, 250 
mg sodium chloride, 110 mg potassium chloride and 1 mL of RPMI to 50 mL of water[30]. 
The dispersion was stirred until a homogenous mixture was obtained. Artificial mucus (0.5 
mL) was placed in the upper chambers of Transwell-24 well plates, whereas 1.5 mL of SILF 
was added in the lower chamber. Then, 0.1 mL of FRET-NPs water dispersion (5 mg/mL) 
was placed on the artificial mucus layer and maintained at r.t. At regular time points (0, 1 h, 
4 h and 24 h), the acceptor medium was collected and fluorescence emission at 575 nm (ex 
488 nm) was recorded on a Varian Cary Eclipse spectrophotometer using 1 cm path length 
quartz. Results are reported as percentage of NPs penetrated through artificial mucus layer. 
The hydrodynamic diameter (DH) of NPs after penetration through the mucus was also 
assessed. As control, mucus-penetrating properties of FRET-NPs pretreated with GSH 10 
mM for 1h were evaluated too.  
 
Cell culture 
A549, Calu-3 and H1299 lung cancer cells were obtained from the American Type 
Culture Collection, cultured at 37°C in a humidified atmosphere containing 5% CO2 and 
grown continuously in DMEM (A549 and Calu-3) or RPMI (H1299) supplemented with 10% 
FBS, 100 unit/mL penicillin and 100 g/mL streptomycin.  
 
MTS assay 
Cells (2 x 104) were placed in 96 well plates and cultured in 200 μL of cell medium with 
or without FBS at 10%. After 24 h, cells were treated with unloaded NPs in the concentration 
range 0.01-50 mg/mL. Cells treated with 0.1% (v/v) Triton-X 100 and fresh media were used 
as a positive and a negative control, respectively. After 24 h of incubation, cells were washed 
with PBS and treated with CellTiter 96® AQueous Cell Proliferation Assay (20 μL per well). 
After further incubation (3 h), the absorbance was read at 490 nm in a microplate reader 
(Tecan Platereader, UK) and the percentage of metabolic activity (%) calculated. 
 
Cell internalization studies 
Quantification of internalized NPs. The percentage of internalization of NPs was initially 
assessed in A549 cells. For these experiments, FRET NPs were employed. Cells were 
seeded in 24 wells/plate (2 x 105 cells/well) in 0.5 mL of  DMEM supplemented with 10% 
FBS. After 24 h of growth at 37° C, the cells were washed and incubated with 125 µg/mL of 
NPs, freshly re-suspended in milli Q water and diluted in medium without Phenol Red and 
FBS. After different time points (1 h, 4 h and 24 h), the media was collected and the 
fluorescence intensity of DiL was read at 575 nm (ex 543 nm) in a microplate reader (Tecan 
Platereader, UK) for NP content. The concentration of NP in the extracellular compartment 
was calculated by means of a standard calibration curve derived for NP suspensions in the 
same cell media at known concentrations (12.5–125 g/mL). The medium alone collected 
from untreated cells was used as control. Then, the amount and the % of NP internalized 
were indirectly calculated.  
FACS measurements. The entry of NPs into A549, Calu-3 and H1299 cells was also 
measured by FACS. For these experiments, FRET NPs were employed in order to evaluate 
the disassembly of NPs inside cells. Cells were seeded in 24 well plate (2 x 105 cells/well) 
in 0.5 mL of  DMEM or RPMI 1640 media supplemented with 10% FBS. After 24 h of growth 
at 37° C, the cells were washed and incubated for 1 h, 4 h and 24 h with 125 µg/mL of NPs, 
freshly re-suspended in milli Q water and diluted in medium without 10% of FBS. After 
incubation with NPs, the cell monolayers were washed and detached from the plates with 
trypsin.  Cells were centrifuged and re-suspended in PBS with Trypan Blue 0.4% v/v. Finally, 
cells were fixed in FACS tubes in ice-cold PBS with 2% p-formaldehyde. DiO and DiL 
fluorescence was acquired by FACS  using a Beckman Coulter Astrios EQ instrument. A 
blue laser at 488 nm (em 513/526 nm) and a yellow/green laser at 561 nm (em 579/616 
nm) were used as excitation source for the detection of DiO and DiL fluorescence, 
respectively. For FRET detection, the laser at 488 nm with em 576/621 nm was used. 104 
events/sample were acquired and analyzed with the Kaluza Analysis 1.3 Software. 
FRET Imaging. A549 cells were incubated with FRET-NPs 125 g/mL (in the cell 
culture media without FBS) at 37° C for 1 h, 4 h and 24 h. Confocal imaging was performed 
using a Zeiss LSM 700 Confocal Laser Scanning Microscope equipped with Argon (488 nm) 
and HeNe (561, 639 nm) lasers and a 40X/1.2 NA water objective. FRET images were 
acquired with ex 488 nm and spectral filters of 505-530 nm and LP 560 nm for DiO and DiL 
detections. Zen 2009 image Software was utilized for image processing. 
Intracellular and extracellular responsiveness of NPs 
Intracellular NP reduction. A549 cells were seeded in 24 well plate (2 x 105 cells/well) 
in 0.5 mL of DMEM supplemented with 10% FBS. After 24 h of growth at 37° C, the cells 
were washed and incubated with 125 µg/mL of FRET-NPs, as described above. After 24 h, 
the cells were washed in order to remove all the NPs not uptaken and incubated again for 
48 h and 72 h. Finally, cells were treated and the samples analysed by FACS as described 
above.  
Extracellular mechanism of NP uptake. A549 cells were seeded in 24 well plate (2 x 
105 cells/well) in 0.5 mL of  DMEM supplemented with 10% FBS. After 24 h of growth at 37° 
C, the cells were washed and pretreated with DTNB 2mM directly dissolved in serum-free 
medium for 30 min, followed by incubation with 125 µg/mL of FRET-NPs in the presence of 
DTNB for 4 h. After incubation, cells were treated and the samples analyzed by FACS as 
described above.  
NP behavior in extracellular media. To determine the stability of NPs in the extracellular 
environment, 0.5 mg of NPs were dispersed in 4 mL of fresh DMEM cell culture medium or 
conditioned medium containing biologically active components obtained from previously 
cultured A549 cells (contact time 1 h) and incubated at 37 °C. Size measurements of the 
samples were taken after 1 h of incubation as described above.  
Extracellular PEG release. Cells (2 x 105 cells/well) were placed in 24 well plate and 
cultured in 500 μL of cell medium without FBS. After 24 h, cells were treated with 1 mg/mL 
of unloaded NPs. At specific time points, the extracellular conditioned media was collected, 
filtrated and centrifuged at 17000 xg for 30 min. Finally, supernatants were collected and 
analyzed for PEG content through Iodine assay. In detail, 50 L of the samples were added 
to 0.125 mL of barium chloride at 5% w/v and 0.125 mL of iodine solution 0.1 M. After 15 
min of incubation, the absorbance of the samples was read at 490 nm in a microplate reader. 
The concentration of PEG was calculated by means of a standard calibration curve derived 
for PEG solution in cell media at known concentrations (1–100 g/mL). The same 
conditioned medium alone treated with iodine was used as control.  
 
Spheroids culture  
Ultra low attachment (ULA) 96 well round bottom plates were employed for the 
culturing of HCT 116 and A549 spheroids. Cells grown as a monolayer were detached using 
trypsin then centrifuged, and the cell number was counted using a haemocytometer. 
Spheroids were seeded by diluting the single-cell suspensions in RPMI-1640 medium 
supplemented with 10% of FBS and 10000 cells per ml were added at a constant volume 
(200 µl) per well in 96 well ULA plates. 6 wells containing the same concentration of cells 
were created for the experiments. The plates were centrifuged at 100 x g for 4 min.  
 
Uptake and distribution of NPs in cancer spheroids  
Spheroids were grown on ULA plates for 3 days to allow for compaction prior to use 
for the penetration and uptake studies.  On day 3 of culture, the media was removed from 
the wells and replaced with 150 µl media containing NPs (NP concentration 125 µg/ml) and 
Hoechst (0.1 µM) and were left to incubate for 24 h. After incubation, the spheroids were 
transferred into 15 ml Falcon conical tubes and washed twice with DPBS (1ml). Accutase (1 
ml) was then added and the tubes were incubated at 37 °C for 5 min with agitation. The 
dissociation of spheroids was aided by mechanical pipetting. The spheroids were then 
centrifuged, fixed with 4% paraformaldehyde (1 ml), washed with DPBS (1 ml) and 
subsequently resuspended in DPBS (0.3 ml) prior analysis by flow cytometry (MoFlo Astrios 
Cell sorter, Beckman Coulter). Cell separation and data analysis via FACS were by a 
published method[31]. 
 
Statistical analysis  
Unless otherwise stated, all data are shown as mean ± standard deviation (SD).Two way 
analysis of variance (ANOVA) was applied for comparison of three or more group means 
(Tukey's multiple comparisons test). P value of <0.05 was considered statistically significant. 
****, ***, **, and * display p < 0.0001, p < 0.001, p < 0.01, and p < 0.05, respectively. 
GraphPad Prism 6 software was used for data analysis. 
Results and Discussion 
The aim of this work was to design novel redox responsive PEGylated NPs intended 
for the local delivery of drugs to the lungs. To this purpose, NPs were designed around linear 
diblock copolymers of polyethylene glycol (PEG)-poly(lactic-co-glycolic acid) (PLGA), as 
PLGA cores can entrap different drugs, external hydrophilic PEG shells have been shown 
to promote NP transport through the lungs after inhalation [23, 32, 33] and PLGA-PEG 
micelles are well-established in clinical applications.[24] However, to introduce responsive 
functionality we aimed to install a disulfide linkage at a highly specific position between 
PLGA and PEG chains, in a manner similar to self-immolative linker strategies.[14, 34, 35] 
This was based on the criteria that the disulfide bond should be easily accessible to soluble 
GSH, and also that reduction should lead to the escape of the PEG layer into solution with 
concomitant formation of further active nucleophiles which could accelerate the degradation 
of the PLGA core. Since the tumor microenvironment can feature reactive thiols and 
reductive species both at extracellular / cell surface proximal sites as well as intracellular 
locations, we envisaged that the NPs would lose their stabilizing PEG regions through the 
cleavage of the disulfide bonds in the extracellular matrix of cancer tissue. In this way we 
aimed to promote the cellular uptake of the still intact PLGA NP cores, and then continue to 
degrade as they encountered further hydrolytic species inside the cancer cells.  
 
Synthesis and characterization of copolymers 
A linear diblock copolymer of PEG and PLGA containing a reducible disulfide linkage 
between PLGA and PEG chains was synthesized through a synthetic approach combining 
the ROP and the Aza-Michael Addition reaction. The synthesis was performed through three 
different steps (Fig. 1B): 1) synthesis of 2-((hydroxymethyl)disulfanyl)ethyl acrylate through 
the reaction of dithiodiethanol with acryloyl chloride; 2) ROP of lactide and glycolide 
monomers using 2-((hydroxymethyl)disulfanyl)ethyl acrylate as initiator, thus obtaining a 
PLGA-ss-ethyl acrylate (PLGA-SS); 3) Aza-Michael Addition between the terminal amine 
group of the mPEG2k and the acrylate group of the functionalized PLGA. All the synthetic 
steps led to high yields of products with few byproducts thus avoiding time-consuming 
purification stages. As control, a comparable non-responsive PLGA-PEG diblock copolymer 
without disulfide bonds, but with the same molecular weight, PEG /lactide/ glycolide molar 
ratio (table 1) as well as thermal properties (table S1) was synthesized (Fig. 1A). In this latter 
case, the copolymer was prepared by ROP of lactide and glycolide monomers initiated by 
mPEG2k with Sn(Oct)2 as catalyst and the final structure was confirmed by 1H-,13C-NMR and 
AT-IR[36]. 
2-((Hydroxymethyl)disulfanyl)ethyl acrylate was accordingly obtained and confirmed as 
previously reported [37]. Addition of DL-lactide and glycolide to 2-
((hydroxymethyl)disulfanyl)ethyl acrylate in the presence of Sn(Oct)2 as catalyst resulted in 
ROP of the monomers initiated from the hydroxyl terminus. 1H-NMR spectra showed the 
expected resonances of the polymer backbone at  1.57-1.61 ppm and  5.20-5.26 ppm 
(methane and methyl protons of poly(lactic acid)) and at  4.70-4.93 ppm (methylene group 
of poly(glycolic acid)). The presence of the terminal acryl group was confirmed by the 
protons between  =5 and =7 ppm.  The conjugation of PEG block to the PLGA-SS was 
finally carried out through Aza-Michael addition in a single synthetic step with simple 
purification. The structure of the diblock copolymer was confirmed by 1H-NMR spectra[38] 
according to the peaks at  1.57-1.61 ppm and  5.17-5.27 ppm (poly(lactic acid)), at  
4.79-4.93 ppm (poly(glycolic acid)), at  3.40 and  3.66-3.68 ppm (polyethylene glycol). 
Signals corresponding to the acrylate vinylic protons between =5 and =7 ppm were not 
apparent after reaction, which indicated the complete addition between PLGA/PEG blocks. 
The Mn of copolymers and the ratios of each block (lactide, glycolide and PEG chains), were 
determined by relative peak integrals of PLGA and PEG proton resonances and confirmed 
by GPC measurements (table 1). In fact, SEC traces of both copolymers (Fig. S3) 
demonstrate no presence of free PEG in the final products.  Hydrophilic/hydrophobic 
properties of intermediates and copolymers were also evaluated by contact angle 
measurements (table S1), thus indicating the effectiveness of the reactions.  
 
 
Preparation and characterization of NPs 
PLGA-PEG and PLGA-S-S-PEG block copolymers were employed to prepare non-
redox responsive and redox responsive NPs (nRR-NPs and RR-NPs), respectively (Fig. 2A). 
NPs were prepared by double emulsion-solvent evaporation techniques and characterized 
in terms of particle size and polydispersity and zeta potential (Fig. 2B-D). The recovery yield 
for the formulations was very high (~75%) indicating that neither polymer precipitation nor 
NP aggregation occurred during preparation. Furthermore, similar colloidal properties of 
both NPs were found, thus highlighting a comparable behaviour of the copolymers. NPs 
exhibited hydrodynamic diameters around 120 nm, low size polydispersity index and high 
negative zeta potential values.   
Exploiting the well known versatility of PLGA-based block copolymers and modulating 
the processing parameters of the emulsification-solvent evaporation technique [39], we 
performed a preliminary encapsulation study aimed at elucidating NP potential to deliver 
both hydrophilic and hydrophobic compounds with comparable molecular weight, alone 
and/or in association. In particular, Rhod6G and Fluo were selected as hydrophilic drug 
models and dissolved in the internal water phase during NP preparation, whereas DiO and 
DiL (FRET pairs molecules) were selected as hydrophobic probes and co-solubilized with 
the copolymers in the organic phase. As summarized in table S2, the formulation processes, 
NP size, polydispersity index and as well as zeta potential values, were not significantly 
influenced by drug entrapment or drug type. At the same time, in all cases, we obtained a 
high entrapment efficiency of the different compounds inside NPs, without observing any 
effect of copolymer type (Fig. 2C).  
To compare the PEG shells thickness on the nRR- and RR-NPs, Fixed Aqueous Layer 
Thickness (FALT) measurements and stability studies in different simulated biological fluids 
were performed. FALT of the outer PEG shell of NPs was determined by measuring ζ of 
NPs as a function of electrolyte concentration. The increase of ionic strength, in fact, 
induced a decrease of as a result of the variation of the slipping plane of the PEG fringe 
away from the surface of NP core [27]. As reported in Fig. 2D, the slope value of the linear 
regression line obtained plotting Log ζ vs sodium chloride concentration gives shell 
thickness (nm). Formulated by copolymers with comparable molecular weight and 
PLGA/PEG molar ratio, and showing as well as same size, nRR- and RR-NPs did not show 
any significant difference in terms of PEG shell thickness (1.2 nm). Both systems showed a 
good colloidal stability in PBS and in NaCl 0.9% w/v (Fig. 2E) up to 3 days of incubation, as 
indicated by the absence of macroscopic aggregates and retention of ‘original ‘ particle size. 
The stability of the systems in Simulated Lung Interstitial Fluids (SILF) was also satisfactory 
over extended time periods (Fig. 2E).  
 
 
Redox responsiveness of NPs 
In order to investigate the redox responsiveness of NPs in a simulated reductive 
environment, stability, release, morphological study and FRET experiments were 
performed. As clearly evidenced in Fig. 3A, RR-NPs showed low colloidal stability under 
different in vitro reducing conditions (GSH and DTT 10 mM), highlighted by the change of 
initial particle size and shape of size distribution curves, compared to nRR-NPs. These 
results indicated a fast aggregation or a disassembly of RR-NPs structure within 30 min 
through the reduction of the disulfide bond in the copolymer chains and the cleavage of the 
link between PLGA and PEG blocks. Changes in the shape of particle size distribution profile 
indicate formation of species with appearance of different subpopulations which may 
indicate lose of original species and appearance of aggregates, potentially formed from 
partly degraded RR-NPs following loos of stabilizing PEG layer and PLGA matrix 
degradation. Comparable results were found when incubating NPs in GSH and DTT ranging 
from 5 to 20 mM at different time points until 24 h of incubation (data not shown). These 
data are in line with the morphological analysis of NPs at both nanoscale and macroscale 
levels in the same conditions. As illustrated in Fig. 3C, TEM images of RR-NPs dispersed in 
PBS without reductive agents showed the spherical morphology and the absence of 
aggregation of NPs comparable to nRR-NPs, with a size in line with the data obtained by 
DLS. After incubation with GSH, a strong deformation of NP shape can be seen, with 
appearance of aggregated clusters. Degradation of RR-NPs is also evident at a macroscopic 
level (Fig. 3D).  
Finally, redox-triggered drug release from NPs was demonstrated through release 
studies of Rhod6G-loaded NPs dispersed in PBS at pH 7.4 with and without GSH 10 mM 
(Fig. 3B). Results showed a sustained release of Rhod6G from RR-NPs in PBS, comparable 
to nRR-NPs. In contrast, with the addition of GSH as triggering agent in the releasing 
medium, a fast Rhod6G release from RR-NPs, completed after 24 h of incubation, was 
found, thus suggesting a rapid disassembly of NP structure as a consequence of PEG 
cleavage and accelerated PLGA degradation. 
 
To confirm these data, FRET studies of NPs loaded simultaneously with DiO and DiL 
probes were carried out. FRET is a mechanism describing energy transfer between two 
light-sensitive molecules, a donor chromophore and an acceptor. The efficiency of this 
energy transfer is inversely proportional to the sixth power of the distance between donor 
and acceptor, making FRET extremely sensitive to small changes in distance. Measurement 
of FRET efficiency is a useful tool to determine if two fluorophores are loaded inside a NP 
system and to monitor its self-assembly and disassembly behaviour in different biological 
conditions and cell models as well as cargo release from NPs [40]. As donor and acceptor, 
we chose the hydrophobic dyes DiO and DiL respectively, since DiO emission spectrum (λex 
/  λem at 488 / 505 nm) overlaps well with the DiL absorption spectrum (λex /  λem at 543 / 575 
nm).  
Excitation at 488 nm of NPs coencapsulating the two chromofluorogenic components and 
dispersed in water showed that the DiL emission at 575 nm dominated over the emission of 
the DiO at 505 nm (Fig. 4A). The intense fluorescence of DiL demonstrates that efficient 
energy transfer occurred, attributable to the close proximity of the co-encapsulated 
compounds in NPs core matrix. However, solubilizing the same formulation in organic 
solvent (DCM) disrupted its core–shell structure, releasing the fluorophores to the external 
medium, reflected in a marked reduction in FRET efficiency ratio (I575/505 reduced from 3.5 
to 0.8). On this basis, we monitored the reduction in FRET efficiency of NPs incubated in 
PBS pH 7.4 with or without GSH 10 mM. Emission spectra of FRET NPs after excitation at 
488 nm (ex DIO) are reported in Figure 4B. After 4 h of incubation of RR-NPs in PBS 
enriched with GSH 10 mM, we observed a strong decrease of DiL emission in comparison 
with all the other samples, although the increase of DiO emission was not detected most 
likely due to its insolubility and aggregation in aqueous media (unlike its solubility in DCM in 
the profile in figure A). From these spectra, then FRET efficiency ratio was calculated (Fig. 
4C). No significant difference in FRET efficiency ratio was observed for nRR-NPs in both 
conditions up to 24 h of incubation. As described above, for RR-NPs, the addition of GSH 
led to a strong decrease in DIL emission and consequently  decreased FRET efficiency ratio 
(I575/505 decreased from 3.5 to 2.1), thus highlighting a progressive release of the dyes from 
NP core, following exposure to GSH and their loos of matrix integrity. No interference 
between the dyes and the thiols of GSH and neither eventual degradation of the dyes was 
found, as shown in Fig. S4, thus confirming a FRET related dissociation of the dyes in a 
reductive environment. In particular, we have performed as control some fluorescent 
experiments with the dyes alone and in association in the presence of GSH 10 mM. No 
modification in the emission spectra of DiO at ex 488, DiL at ex 543 and DiO/DiL mixture 
(FRET effect) at ex 488 was observed. 
 
Preparation of anticancer NPs 
 
Since the NPs have been developed for a potential anticancer application, Docetaxel 
(DTX), a lipophilic anticancer drug approved for lung cancer treatment was loaded inside 
NPs at 10% compared to copolymer weight. In figure 5A, properties of DTX-loaded NPs are 
shown, in terms of size, polydispersity index, yield of the preparation, surface charge and 
drug loading. In this context, nRR-NPs and RR-NPs showed similar entrapment ability of 
DTX, as for the other drug models previously tested. At the same time, release studies of 
DTX from NPs by dialysis were in line with the results obtained from NPs loaded with 
Rhodamine 6G. In figure 5B, in fact, it is possible to note that PLGA-S-S-PEG NPs displayed 
a sustained release pattern of DTX in PBS, comparable to PLGA-PEG NPs in the same 
acceptor medium, which was unaffected by the presence of reductive agents. In particular, 
around the 50% of the entrapped DTX was released in 14 days, compared with the free drug 
in the same conditions (inset). On the contrary, with the addition of GSH in the releasing 




Interactions with mucus 
A key parameter to consider in the case of inhalation therapies is the ability to 
overcome the biological barriers imposed by lungs, especially the mucus barrier, which 
reduces the chances of NPs to reach epithelial cells. Accordingly, NPs were assessed for 
their abilities to interact with an artificial mucus layer, in terms of both mucoadhesive and 
mucus-penetrating properties. Mucoadhesion studies were performed by measuring the 
turbidity at 650 nm (Fig. 6A), as well as size and zeta potential values (Fig. 6B) of NP 
dispersions in mucin solutions over time. As evidenced in the graphs, all the experiments 
showed no interaction between both NP systems and mucin up to 24 h of incubation. As 
expected, the presence of PEG shell allowed a time dependent NP penetration through the 
artificial mucus layer, in line with previous studies on NPs with low MW PEG coatings [41]. 
In fact, a high percent of still intact fluorescent NPs, co-loaded with DiO and DiL probes, 
was found in the acceptor medium after 24 h (Fig. 6C). In order to discriminate NPs from 
the loaded dyes that could be released, we exploited the FRET mechanism, as described 
above, thus demonstrating that NP structure integrity was still intact after permeation, and 
the unchanged FRET profiles in (Fig. 6E), as well as by the size distribution curves of 
collected NPs dispersed in the SILF medium (Fig. 6D).  To confirm the role of PEG in NP 
penetration through the artificial mucus, the experiment was performed also with NPs pre-
treated with GSH as control. In figure S5, as expected no significant differences in the 
spectra of nRR-NPs pre-treated with GSH was found. On the contrary, following GSH 
treatment and the subsequent release of PEG shedding from RR-NPs, a marked reduction 
of penetration extent of RR-NPs was observed through the quenching of the FRET emission 
spectra.   
 
Cellular uptake studies 
In order to investigate the internalization of NPs into cancer cells we carried out uptake 
experiments of labeled NPs in different lung cancer cell lines. To this aim, we again 
employed FRET NPs. By monitoring FRET it was possible to follow the cellular 
internalization, to assess stability and NP integrity after cell internalization, as well as to 
‘model’ drug release over time. The experiment was performed at 1 h, 4 h and 24 h with 
both RR-NPs and nRR-NPs, applied at 125 g/mL, which was shown to be a concentration 
well tolerated by cells (Fig. S6). 
Initial experiments quantified the amount of NPs internalized by A549 cells in terms of 
percentage of the applied dose (Fig. 7A). A significantly higher uptake of RR-NPs in 
comparison with nRR-NPs was shown at all the incubation times. In fact, after 1 h of 
incubation, 13% and 30% of applied nRR-NPs and RR-NPs, respectively, entered the A549 
cells, increasing to around 55% and 90%, respectively, after 24 h.  
FACS measurements and confocal imaging were performed to further investigate the 
uptake rate and the fate of NP after internalization. To establish appropriate experimental 
conditions to measure FRET signals by FACS, we first analysed cells treated with DiO and 
DiL either individually or in combination, according the method of Banning et al [42]. Gating 
was applied to living cells according to forward and sideward scatter (FSC/SSC) and 
adjusted photomultiplier tube voltages and compensation for DiO and DiL to specifically 
assess FRET in double positive cells. Thus, via excitation at 488 nm and employing 
emission filters at 576/621 nm, FRET was plotted against DiL and a gate was introduced to 
determine the amount of FRET-positive cells. This gate was adjusted to FRET-negative cells 
treated with DiL and DiO alone. In figure 7B, the mean fluorescent intensities (MFI) of DiL 
and FRET of A549 cells after treatment with NPs at different times, are represented. Through 
DiL emission analysis (ex 561 nm-  em 579/616 nm), we monitored the uptake rate from 
the cells of the drug model, both delivered from NPs as well as eventually released from 
them. Also in this case, we observed a significantly higher uptake of DiL loaded in RR-NPs 
in comparison with nRR-NPs, especially after 4 h (0.5 and 1.5 MFI for nRR-NPs and RR-
NPs respectively) and 24 h of treatment (around 2 and 9 MFI for nRR-NPs and RR-NPs 
respectively). Thus considering the MFI of FRET, we have an indication of the amount of 
intact NPs internalized by cells. Again, we found that uptake of RR-NPs was much more 
pronounced than nRR-NPs especially after 24 h of time contact (0.2 and 0.6 MFI for nRR-
NPs and RR-NPs respectively). Comparable results were obtained in H1299 cells (Fig. 
S7B). Although the same trends in terms of internalization of nRR-NPs compared to RR-
NPs were found, there were differences in overall FRET MFI over short incubation times in 
the case of Calu-3 cells (Fig. S7A), probably due differences in the cell line attributes [43].  
Results obtained by FACS were confirmed by confocal imaging. In the case of A549 cells 
(Fig. 7C), after 1 h of incubation with NPs, yellow fluorescence was observed in the cell 
interiors, produced by the FRET mechanism between DiO and DiL. The intensity of 
fluorescence was greater for cells treated with RR-NPs compared to nRR-NPs, indicative of 
higher overall uptake. This effect was more evident after 4 h and 24h of incubation. 
Additionally, in the case of RR-NPs, an increase in DiO green fluorescence was observable 
with time, suggesting the release of the dyes following faster intracellular redox- responsive 
disassembly of the RR-NP cores.  
To further validate the exploitation of the FRET mechanism related to the co-
localization of the probes inside NPs at cell level, we carried out a preliminary study as 
control with a cell membrane model as previously reported[40]. Small unilamellar vesicles 
(SUV) were employed as a membrane model and prepared as reported by Li et al [44]. 
FRET NPs or the free probes (0.6 mg/mL) were mixed with the SUV solution (2mg /mL) in 
order to examine the release of the probes from NPs to lipid bilayers. At different time points, 
fluorescence emission spectra (lex 488) were recorded and the IF575/505 calculated as 
indication of the FRET efficiency. In figure S8, it is clearly evident that a decrease of FRET 
occurred over time for the free dyes due to their partition in the membrane bilayer, as 
expected from prior literature[40]. In contrast, FRET NPs showed the same spectra and the 
same FRET efficiency at all time points tested, thus indicating no release of the entrapped 
dyes outside the cells. 
The higher and faster uptake of RR-NPs, in comparison with nRR-NPs, in the different 
cell lines after short incubation times, could be attributed to an initial extracellular reduction 
of the linkage between the PLGA core and the PEG shell, in line with work published for 
analogous DNA-releasing polymers. [19] In our case this reduction was likely to lead to 
shedding of some of the PEG layer, consequently reducing the ‘steric’ barrier to cell 
internalization[45]. It has previously been shown that PEG-poly(lactide) co-polymers, with 
oligo-cysteine cross-links which stabilized micellar structures, were internalized more 
efficiently than non-cross-linked PEG-poly(lactide) micelles, indicating that structural 
integrity of NPs is important in cell internalization [46]. Thus, the PEG shell in our block co-
polymers was key to initial colloidal stability, but removal of, at least some of this shell, was 
likely to have been critical in enhancing the cell membrane interaction and subsequent cell 
entry. In this context we noted, a comparable stability of the RR-NPs and nRR-NPs systems 
in cell culture media with or without the presence of serum (Fig. S9).  
 
Intracellular and extracellular responsiveness of NPs 
To investigate further the different intracellular responsiveness of NPs to redox 
mechanisms, uptake experiments of NPs into A549 cells were carried out over 24 h of 
incubation and the FRET effect monitored. In figure 8A, the percentage of FRET-positive 
cells and the ratio between the MFI of FRET (ex 488 nm- em 576/621 nm) and DiO (ex 488 
nm-em 513/526 nm) are reported. After internalization of nRR-NPs and RR-NPs, the 
number of FRET-positive cells decreased by 20% (from 40 % to 32%) and 50% (from 40% 
to 20%) respectively. At the same time the FRET/DiO MFI ratio of cells treated with nRR-
NPs did not show any change over time, whereas a strong decrease of this value was 
evident in the case of cells treated with RR-NPs. This indicated the decrease of the FRET 
effect, as well as the increase of DiO signals, due to the faster disassembly of NPs within 
the intracellular space.  
To test if extracellular reductive mechanisms were involved in the different 
internalization rates of NPs, uptake studies of FRET NPs in the presence of DTNB were 
carried out. DTNB is a cell impermeable agent but reacts with free thiols thus blocking the 
action of any free sulfhydryls present in the extracellular environment. These experiments 
showed that DTNB did not cause any modification in the cellular uptake of nRR-NPs, relative 
to DTNB free conditions (Fig. 8B), but produced a strong decrease of RR-NP uptake. This 
decrease was observed both in terms of DiL MFI as well as FRET/DiO MFI ratio, and the 
values obtained were comparable to the control formulation. Finally, to confirm the 
extracellular responsiveness of the carrier, colloidal stability studies of NPs in conditioned 
cell medium and PEG release rate in the extracellular compartment were conducted. Firstly, 
NPs were dispersed in the conditioned medium employed to grow A549 cells for 4 h. After 
1 h of incubation, RR-NPs were no longer colloidally stable, compared to nRR-NPs and to 
the same carrier dispersed in fresh cell culture medium (Fig. 8C). At the same time, a much 
faster PEG release from RR-NPs in the extracellular compartment of cancer cell cultures 
was found (Fig. 8D). In particular, we found in the cell media around 15% and 40% of PEG 
released compared to the applied doses for nRR-NPs and RR-NPs respectively, after 4h of 
treatment.  Taken together, these results demonstrated the effective responsiveness of RR-
NPs to the specific extracellular environment, which we attribute to the accessibility to cell-
secreted thiolated species of the disulfide bonds between the PLGA and PEG copolymer 
moieties. In turn, the breaking of these links led to release of PEG chains and subsequent 
enhanced NP hydrophobicity, which was manifest by colloidal instability, and enhanced 
internalization of NPs by the cells in culture.   
 
Uptake and distribution of NPs in cancer spheroids  
With the aim to investigate further the potential of NPs to penetrate cancer tissues, 3D- 
spheroids models of HCT 116 and A549 cancer cells were employed[31]. The morphology 
of the 3D- cell spheroids is shown in Fig. 9. In this experiment, we employed 125 g/mL of 
FRET NPs in a 24 h treatment. As depicted in Fig. 9, in both spheroid models, RR-NPs 
showed better penetration, compared to nRR-NPs, reaching all spheroid regions, the outer 
rim of proliferating cells, the middle viable layer of quiescent cells, but also the internal 
necrotic core of the spheroid, as judged from the comparisons with penetration of the 
standard probe[31]. The difference in nRR-NPs and RR-NPs penetration could again be 
attributed to the cleavage of the PEG shell of the RR-NPs formulation in the extracellular 
environment of the spheroid and hence improved cellular internalization; consistent with the 
data on cellular uptake in 2D cell monolayers. The data hence suggested that the RR-NPs 
retained an ability to permeate through the cancer cell aggregates, as well as promoting 




A new linear and amphiphilic diblock copolymer containing a reducible disulfide bridge 
specifically located via ethanoate ester links between poly(lactic-co-glycolic acid) (PLGA) 
and polyethylene glycol (PEG) blocks was synthesized. The polymer was employed to form 
redox responsive nanoparticles which exhibited ability to penetrate mucus layer and high 
colloidal stability in simulated biological fluids. However a fast disassembly/aggregation of 
NPs in conditions simulating intracellular reductive environment was found. Cellular 
internalization  studies performed in in vitro 2D- and 3D- lung cancer models, indicated 
enhanced internalization of the redox-responsive NPs, compared to nRR-NP analogues 
without the disulfide link between PLGA and PEG, which we suggest arises from a double 
redox responsive behaviour of the NPs via loss of colloidally-stabilising PEG chains in the 
region of cancer cell surfaces, as well as the enhanced intracellular breakdown of the 
particles due to cytosolic reduction. We suggest that the chemical design principles of 
placing the reductively-cleavable linker via a critical ethanoate ester spacer between the 
hydrophilic and hydrophobic regions of this polymer, coupled with the mucus penetrating 
properties of short/medium PEG chains and the well-established regulatory profile of PLGA 
blocks, renders our approach promising for future in vivo applications. These experiments 
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